Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
The first immunotherapy approved in the U.S. to treat head and neck cancer has failed a big test, but it's unclear if the FDA will exercise its right to pull it from the market. Merck (NYSE: MRK) announced late Monday that its blockbuster cancer drug ...
Merck immunotherapy fails to improve survival in head and neck cancerReuters
Merck: Keytruda trial comes up short in head and neck cancer, but FDA approval staysSTAT
(pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous ...Business Wire (press release)
all 5 news articles »
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uRPnXF